Lastra Guido, Habibi Javad, Whaley-Connell Adam T, Manrique Camila, Hayden Melvin R, Rehmer Jenna, Patel Kamlesh, Ferrario Carlos, Sowers James R
Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, Missouri 65212, USA.
Endocrinology. 2009 Jun;150(6):2561-8. doi: 10.1210/en.2008-1391. Epub 2009 Feb 26.
Renin is the rate-limiting enzyme in renin-angiotensin system (RAS) activation. We sought to determine the impact of renin inhibition on whole-body insulin sensitivity and skeletal muscle RAS, oxidative stress, insulin signaling, and glucose transport in the transgenic TG(mRen2)27 rat (Ren2), which manifests increased tissue RAS activity, elevated serum aldosterone, hypertension, and insulin resistance. Young (aged 6-9 wk) Ren2 and age-matched Sprague Dawley control rats were treated with aliskiren [50 mg/kg . d, ip] or placebo for 21 d and administered an ip glucose tolerance test. Insulin metabolic signaling and 2-deoxyglucose uptake in soleus muscle were examined in relation to tissue renin-angiotensin-aldosterone system [angiotensin (Ang) II, mineralocorticoid receptor (MR), and Ang type I receptor (AT(1)R)] and measures of oxidative stress as well as structural changes evaluated by light and transmission electron microscopy. Ren2 rats demonstrated systemic insulin resistance with decreased skeletal muscle insulin metabolic signaling and glucose uptake. This was associated with increased Ang II, MR, AT(1)R, oxidative stress, and reduced tyrosine insulin receptor substrate-1 phosphorylation, protein kinase B/(Akt) phosphorylation and glucose transporter-4 immunostaining. The Ren2 also demonstrated perivascular fibrosis and mitochondrial remodeling. Renin inhibition improved systemic insulin sensitivity, insulin metabolic signaling, and glucose transport along with normalization of Ang II, AT(1)R, and MR levels, oxidative stress markers, fibrosis, and mitochondrial structural abnormalities. Our data suggest that renin inhibition improves systemic insulin sensitivity, skeletal muscle insulin metabolic signaling, and glucose transport in Ren2 rats. This is associated with reductions in skeletal muscle tissue Ang II, AT(1)R, and MR expression; oxidative stress; fibrosis; and mitochondrial abnormalities.
肾素是肾素-血管紧张素系统(RAS)激活中的限速酶。我们试图确定在转基因TG(mRen2)27大鼠(Ren2)中肾素抑制对全身胰岛素敏感性以及骨骼肌RAS、氧化应激、胰岛素信号传导和葡萄糖转运的影响,该大鼠表现出组织RAS活性增加、血清醛固酮升高、高血压和胰岛素抵抗。将年轻(6 - 9周龄)的Ren2大鼠和年龄匹配的斯普拉格-道利对照大鼠用阿利吉仑[50 mg/kg·d,腹腔注射]或安慰剂治疗21天,并进行腹腔注射葡萄糖耐量试验。研究了比目鱼肌中的胰岛素代谢信号传导和2-脱氧葡萄糖摄取与组织肾素-血管紧张素-醛固酮系统[血管紧张素(Ang)II、盐皮质激素受体(MR)和血管紧张素I型受体(AT(1)R)]以及氧化应激指标的关系,以及通过光学显微镜和透射电子显微镜评估的结构变化。Ren2大鼠表现出全身胰岛素抵抗,骨骼肌胰岛素代谢信号传导和葡萄糖摄取减少。这与Ang II、MR、AT(1)R增加、氧化应激以及酪氨酸胰岛素受体底物-1磷酸化、蛋白激酶B/(Akt)磷酸化和葡萄糖转运蛋白-4免疫染色减少有关。Ren2大鼠还表现出血管周围纤维化和线粒体重塑。肾素抑制改善了全身胰岛素敏感性、胰岛素代谢信号传导和葡萄糖转运,同时使Ang II、AT(1)R和MR水平、氧化应激标志物、纤维化和线粒体结构异常恢复正常。我们的数据表明,肾素抑制可改善Ren2大鼠的全身胰岛素敏感性、骨骼肌胰岛素代谢信号传导和葡萄糖转运。这与骨骼肌组织中Ang II、AT(1)R和MR表达的减少、氧化应激、纤维化和线粒体异常的减少有关。